Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: a patient‐level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To evaluate the impact of relevant patient‐level characteristics on the efficacy and safety
of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and …
of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and …
[PDF][PDF] Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of …
SCB MD10 - 2019 - core.ac.uk
Aim: To evaluate the impact of relevant patient-level characteristics on the efficacy and
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials …
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials …
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin… - Diabetes, Obesity & …, 2020 - search.ebscohost.com
Aim: To evaluate the impact of relevant patient‐level characteristics on the efficacy and
safety of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials …
safety of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials …
[PDF][PDF] Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of …
SCB MD10 - 2019 - academia.edu
Aim: To evaluate the impact of relevant patient-level characteristics on the efficacy and
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials …
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials …
[HTML][HTML] Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled …
VR Aroda, MS Capehorn, L Chaykin… - Diabetes, Obesity & …, 2020 - ncbi.nlm.nih.gov
Aim To evaluate the impact of relevant patient‐level characteristics on the efficacy and safety
of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and …
of subcutaneous, once‐weekly semaglutide in subjects with type 2 diabetes. Materials and …
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: a patient-level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin… - Diabetes, Obesity …, 2020 - research.regionh.dk
AIM: To evaluate the impact of relevant patient-level characteristics on the efficacy and
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes …
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes …
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin, JP Frias… - ikm.ku.dk
Aim: To evaluate the impact of relevant patient-level characteristics on the efficacy and
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials …
safety of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials …
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin… - Diabetes, Obesity & …, 2019 - europepmc.org
Aim To evaluate the impact of relevant patient-level characteristics on the efficacy and safety
of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials and …
of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials and …
Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin… - Diabetes, obesity & …, 2020 - pubmed.ncbi.nlm.nih.gov
Aim To evaluate the impact of relevant patient-level characteristics on the efficacy and safety
of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials and …
of subcutaneous, once-weekly semaglutide in subjects with type 2 diabetes. Materials and …
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the …
VR Aroda, MS Capehorn, L Chaykin, JP Frias… - Diabetes, Obesity and …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Aim</jats: title>< jats: p> To
evaluate the impact of relevant patient‐level characteristics on the efficacy and safety of …
evaluate the impact of relevant patient‐level characteristics on the efficacy and safety of …